Interpace Biosciences logo
Interpace Biosciences IDXG
$ 1.91 -3.29%

Annual report 2025
added 03-30-2026

report update icon

Interpace Biosciences Financial Statements 2011-2026 | IDXG

Annual Financial Statements Interpace Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

7.34 M 4.12 M 5.96 M 4.66 M 22.3 M 16.2 M 28.6 M 25.3 M 17.3 M 7.55 M 4.18 M 23.2 M 86.5 M 112 M 95.7 M

Shares

4.42 M 4.39 M 4.32 M 4.24 M 4.14 M 4.03 M 3.75 M 2.82 M 1.58 M 182 K 155 K 149 K 147 K 146 K 144 K

Historical Prices

1.66 0.94 1.38 1.1 5.39 4.02 7.91 9.2 10.8 41.7 27 156 579 775 641

Net Income

24.6 M 6.7 M 1.95 M -22 M -14.9 M -26.5 M -26.7 M -12.2 M -12.2 M -8.33 M -11.4 M -16.1 M -4.56 M -25.5 M -11.9 M

Revenue

38.7 M 46.9 M 40 M 31.8 M 8.2 M 32.4 M 24.1 M 21.9 M 15.9 M 13.1 M 9.43 M 120 M 151 M 127 M 157 M

Cost of Revenue

14.6 M 17 M 15 M 13.6 M 14.3 M 21.7 M 15.9 M 10.2 M 7.36 M 6.64 M 6.91 M 1.27 M 17.4 M 16.4 M 19.7 M

Gross Profit

24.1 M 29.9 M 25.1 M 18.2 M 18.8 M 10.7 M 8.19 M 11.7 M 8.54 M 6.44 M 2.52 M 18.5 M 24.4 M 26.9 M 32.5 M

Operating Income

4.08 M 8.11 M 3.96 M -3.62 M -6.34 M -26.1 M -26.4 M -12.6 M -6.29 M -6.44 M -40.4 M -17.8 M -1.44 M -25.2 M -4.7 M

Interest Expense

- - -252 K -1.21 M -366 K 549 K 440 K 331 K 433 K 14 K -93 K 602 K - -28 K -14 K

EBITDA

4.51 M 8.41 M 4.98 M -1.06 M -962 K -22.1 M -16 M -4.09 M -5.39 M -7.4 M -23.2 M -9.84 M -2.85 M 1.02 M -1.66 M

Operating Expenses

20 M 21.8 M 21.1 M 21.8 M 25.1 M 37.3 M 28.4 M 19 M 17.2 M 17.6 M 29.6 M 29.2 M 28.7 M 27.9 M 37.2 M

General and Administrative Expenses

9.48 M 9.49 M 9.36 M 11 M 10.7 M 20.8 M 14.5 M 8.5 M 9.15 M 10.5 M 16.9 M 29.2 M 28.7 M 27.9 M 34.3 M

All numbers in USD currency

Quarterly Income Statement Interpace Biosciences

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

4.42 M 4.42 M 4.42 M 4.41 M 4.39 M 4.38 M 4.37 M 4.35 M 4.32 M 4.31 M 4.31 M 4.3 M 4.24 M 4.23 M 4.21 M 4.2 M 4.16 M 4.1 M 4.09 M 4.06 M 4.04 M 4.03 M 4 M 3.92 M 3.82 K 3.81 M 3.52 M 2.87 M 28.2 K 27.9 M 27.9 M 27.8 M 22 M 9.66 M 4.29 M 2.18 M 1.82 M 1.82 M 1.78 M 1.77 M 15.7 M 15.2 M 15 M 15.4 M 14.9 M 14.9 M 14.8 M 15.2 M 14.7 M 14.7 M 15 M 15 M 14.6 M 14.6 M 14.5 M 14.7 M 14.5 M 14.4 M 14.5 M

Net Income

911 K -640 K 1.65 M - 1.68 M 2.44 M 708 K - -614 K 175 K 351 K - -14.2 M -3.94 M -2.25 M - -3.56 M -3.45 M -4.21 M -8.14 M -6.23 M -5.58 M -6.49 M -10.7 M -7.45 M -5.3 M -3.33 M -4.3 M -3.13 M -2 M -3.28 M - -3.4 M -6.39 M 2.33 M - -8 M -2.84 M -5.3 M - -5.4 M -7.49 M -4.61 M - -4.45 M -2.66 M -1.61 M - -2.14 M -883 K 2.13 M - -1.02 M -439 K -272 K - -202 K -895 K -550 K

Revenue

8.76 M 9.23 M 11.5 M - 12.3 M 12 M 10.2 M - 9.08 M 11 M 9.83 M - 1.27 M 1.96 M 2.45 M - 8.06 M 11.2 M 9.83 M - 8.25 M 5.45 M 9.06 M - 7.72 M 6.27 M 6.01 M - 5.75 M 5.5 M 4.81 M - 4.2 M 3.86 M 3.47 M - 3.32 M 3.61 M 3.04 M - 2.51 M 2.25 M 2.12 M - 29.2 M 31.6 M 32.8 M - 34.3 M 37.2 M 42.9 M - 31.8 M 27.8 M 31.7 M - 36.1 M 38.6 M 44.3 M

Cost of Revenue

3.32 M 3.96 M 4.14 M - 4.39 M 4.24 M 3.87 M - 4.12 M 4.19 M 3.85 M - 3.46 M 3.56 M 3.26 M - 3.62 M 5.8 M 5.32 M - 5.19 M 3.85 M 6.11 M - 4.84 M 3.03 M 2.62 M - 2.76 M 2.25 M 2.58 M - 2.07 M 1.88 M 1.77 M - 1.85 M 1.84 M 1.18 M - 1.8 M 1.85 M 1.57 M - 24.4 M 25.8 M 26.7 M - 4.23 M 4.91 M 4.16 M - 4.08 M 4.07 M 4.58 M - 4.17 M 5.7 M 5.28 M

Gross Profit

5.44 M 5.28 M 7.37 M - 7.9 M 7.81 M 6.31 M - 4.95 M 6.84 M 5.98 M - 4.73 M 3.83 M 4.66 M - 4.44 M 5.36 M 4.52 M - 3.05 M 1.6 M 2.95 M - 2.89 M 3.24 M 3.39 M - 2.99 M 3.25 M 2.23 M - 2.13 M 1.98 M 1.7 M - 1.47 M 1.77 M 1.86 M - 707 K 402 K 543 K - 3.85 M 5.19 M 5.12 M - 4.7 M 6.85 M 8.47 M - 5.94 M 6.57 M 7.37 M - 7.68 M 7.93 M 8.16 M

Operating Income

1.14 M -468 K 1.83 M - 2.3 M 2.63 M 1.11 M - -16 K 832 K 675 K - -780 K -1.91 M -977 K - -1.82 M -2.91 M -3.82 M - -6 M -5.77 M -6.35 M - -7.13 M -5.35 M -3.18 M - -2.46 M -1.9 M -3.25 M - -3.1 M -3.6 M 3.7 M - -6.49 M -2.89 M -3.8 M - -6.65 M -7.71 M -6.12 M - -3.2 M -1.06 M -414 K - -2.05 M -847 K 2.25 M - -756 K -316 K -221 K - 195 K -1.07 M -1.39 M

Interest Expense

-10 K -10 K - - 10 K 14 K -82 K - -252 K -174 K 19 K - -217 K 37 K 161 K - 49 K -168 K 135 K - 138 K 167 K 109 K - 111 K 91 K 129 K - 248 K 33 K 111 K - 40 K -8 K -36 K - 4 K 3 K 6 K - 969 K 884 K 848 K - - - - - 3 K -24 K -9 K - - -15 K -1 K - -48 K -26 K -65 K

EBITDA

1.26 M -367 K 1.92 M - 2.39 M 2.7 M 1.17 M - 184 K 1.13 M 1.03 M - -480 K -1.61 M -196 K - 2.52 M 37 K -2.28 M - -1.9 M -3.06 M -5.03 M - -3.97 M -3.43 M -2.23 M - 115 K -188 K -2.39 M - -282 K -1.66 M 4.67 M - -3 M -504 K -2.54 M - -2.88 M -5.21 M -4.93 M - -1.87 M -225 K 43 K - -1.13 M -270 K 2.54 M - 734 K 680 K 280 K - 2.55 M 493 K -604 K

Operating Expenses

4.29 M 5.74 M 5.54 M - 5.6 M 5.17 M 5.2 M - 4.97 M 6 M 5.3 M - 5.51 M 5.74 M 5.64 M - 6.26 M 8.26 M 8.33 M - 9.06 M 7.37 M 9.3 M - 10 M 8.59 M 6.57 M - 5.46 M 5.15 M 5.48 M - 5.23 M 5.57 M -2 M - 7.96 M 4.66 M 5.66 M - 7.36 M 8.12 M 6.67 M - 7.06 M 6.26 M 5.53 M - 6.75 M 7.7 M 6.22 M - 6.7 M 6.89 M 7.59 M - 7.48 M 9 M 9.55 M

General and Administrative Expenses

2.06 M 2.66 M 2.55 M - 2.54 M 2.14 M 2.24 M - 2.12 M 2.89 M 2.49 M - 2.77 M 2.98 M 2.89 M - 2.57 M 3.33 M 2.98 M - 3.8 M 3.98 M 4.84 M - 4.49 M 2.79 M 2.74 M - 2.08 M 1.73 M 2.17 M - 2.12 M 2.79 M 1.52 M - 2.86 M 2.02 M 2.82 M - 2.5 M 3.43 M 3.34 M - 6.93 M 6.26 M 5.53 M - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Interpace Biosciences IDXG
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Interpace Biosciences plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Agilent Technologies Agilent Technologies
A
$ 116.17 0.54 % $ 35.3 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Illumina Illumina
ILMN
$ 128.13 0.2 % $ 20.4 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.67 - $ 2.22 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 84.55 0.26 % $ 5.71 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 416.87 1.54 % $ 12 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 25.33 3.56 % $ 704 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 27.56 0.33 % $ 20 B niderlandNiderland
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
CareDx, Inc CareDx, Inc
CDNA
$ 21.59 1.7 % $ 1.15 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Senseonics Holdings Senseonics Holdings
SENS
$ 7.13 1.13 % $ 298 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 52.73 0.01 % $ 2.68 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 16.0 -1.9 % $ 484 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 468.52 -0.22 % $ 177 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 0.64 -1.51 % $ 61.9 M irlandaIrlanda
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 60.4 -0.89 % $ 3.61 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 172.02 1.33 % $ 8.53 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Guardant Health Guardant Health
GH
$ 90.04 1.27 % $ 11.3 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Neogen Corporation Neogen Corporation
NEOG
$ 9.51 -0.37 % $ 2.06 B usaUSA
Biomerica Biomerica
BMRA
$ 2.16 0.86 % $ 4.96 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.09 -0.81 % $ 383 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 100.76 -1.38 % $ 8.31 B irlandaIrlanda
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 263.91 0.06 % $ 22 B usaUSA
Celcuity Celcuity
CELC
$ 122.87 1.52 % $ 5.75 B usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 8.6 3.68 % $ 1.1 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 4.76 -0.31 % $ 441 M usaUSA
Natera Natera
NTRA
$ 205.87 1.04 % $ 20.3 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 196.59 0.19 % $ 21.8 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA